SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...
Shares of the thinly traded nanocap biotech TRACON Pharmaceuticals Inc (NASDAQ: TCON) were rallying Thursday. What Happened Tracon, which specializes in novel therapeutics for cancer, said it has ...
SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development ...
The ENVASARC registration trial is a multi-center, open-label, randomized, non-comparative, parallel cohort study at approximately 25 top cancer centers in the United States. TRACON expects the trial ...
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam ...
TRACON Pharmaceuticals TCON shares are trading lower Thursday morning after the company released the results of a six-month independent data monitoring committee (IDMC) review for the ongoing ENVASARC ...
The Dow Jones closed higher by more than 250 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders ...
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results